Malaria Information and Prophylaxis, by Country [M]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Macau SAR (China) None Not Applicable Not Applicable Not Applicable
Macedonia None Not Applicable Not Applicable Not Applicable
Madagascar All areas, except rare cases in Antananarivo. Chloroquine P. falciparum 85%,

P. vivax 5-10%,

P. ovale 5%

All areas except Antananarivo: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6.

Antananarivo: Mosquito avoidance only.

Madeira Islands (Portugal) None Not Applicable Not Applicable Not Applicable
Malawi All Chloroquine P. falciparum 90%,

P. malariae, P. ovale, and P. vivax 10% combined

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Malaysia Present in rural areas. None in Georgetown, Kuala Lampur, and Penang State (includes Penang Island). Chloroquine P. falciparum,
P. vivax,
P. malariae,
P. knowlesi,
and P. ovale.
Rural areas: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Maldives None Not Applicable Not Applicable Not Applicable
Mali All Chloroquine P. falciparum >85%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Malta None Not Applicable Not Applicable Not Applicable
Marshall Islands None Not Applicable Not Applicable Not Applicable
Martinique (France) None Not Applicable Not Applicable Not Applicable
Mauritania All areas except Dakhlet-Nouadhibou and Tiris-Zemour in the north Chloroquine P. falciparum >85%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Mauritius None Not Applicable Not Applicable Not Applicable
Mayotte (France) Rare cases Chloroquine P. falciparum 93%,
P. vivax 5%,
P. malariae and P. ovale 2%
Mosquito avoidance only
Mexico Present in Chiapas and southern part of Chihuahua. Rare cases in Campeche, Durango, Jalisco, Nayarit, Quintana Roo, San Luis Potosi, Sinaloa, Sonora, and Tabasco. No malaria along the United States-Mexico border. None P. vivax 100% States of Chiapas and southern part of Chihuahua: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,6 or tafenoquine6. States of Campeche, Durango, Jalisco, Nayarit, Quintana Roo, San Luis Potosi, Sinaloa, Sonora, and Tabasco: Mosquito avoidance only.

 

Micronesia, Federated States of; Includes: Yap Islands, Pohnpei, Chuuk, and Kosrae None Not Applicable Not Applicable Not Applicable
Moldova None Not Applicable Not Applicable Not Applicable
Monaco None Not Applicable Not Applicable Not Applicable
Mongolia None Not Applicable Not Applicable Not Applicable
Montenegro None Not Applicable Not Applicable Not Applicable
Montserrat (U.K.) None Not Applicable Not Applicable Not Applicable
Morocco None Not Applicable Not Applicable Not Applicable
Mozambique All Chloroquine P. falciparum >90%,

P. malariae, P. ovale, and P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: March 27, 2019